Ebitda English news | Ebitda, Latest News & Live Updates in English | English News (Latest English News) at Lokmattimes.com

Biopharmaceuticals major Biocon Ltd on Thursday reported net profit of Rs 257 crore in the fourth quarter of FY21, up 95 per cent from Rs 132 crore in Q4 FY20.The was largely driven by biosimilars, research services and generics businesses. The company's Q4 FY21 consolidated revenue grew 26 per cent to Rs 2,044 crore from Rs 1,621 crore in Q4 FY20.Earnings before interest, taxes, depreciation and amortisation (EBITDA) was Rs 641 crore versus Rs 382 crore in the same period.Biocon gained Rs 160 crore arising on fair valuation of Bicara Therapeutics Inc due to loss of control from subsidiary to associate reported under 'other income' for the quarter.Executive Chairperson Kiran Mazumdar-Shaw said the company's determination to keep investing in science to stay a step ahead of the pandemic is reflected in 19 per cent rise in our gross R&D spends."As a science-led company, we are contributing to the national fight against the pandemic through several initiatives spanning diagnostic tests, vaccination and therapies towards combating Covid-19," she said.The Biocon Group is catering to the countrywide demand for Remdesivir, Itolizumab and CytoSorb. Syngene, through its vaccination centre, is offering immunisation services for Biocon Group employees as well as others operating in Electronic City at Bengaluru."Despite the challenges posed by the second Covid-19 wave in India, we will endeavour to have safe and uninterrupted operations and enable access to life-saving medicines for our patients and customers," said Mazumdar-Shaw.On account of the uncertainty created by unprecedented second wave of Covid-19 pandemic and continued investments in R&D and capex, the board of directors decided it will not be appropriate to declare a dividend for FY21.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

EbitdaFOLLOW

Ebitda, Latest News

Dr Reddy's Laboratories on Friday reported a consolidated net profit of Rs 554 crore for the quarter ended March, down 28 per cent from Rs 764 crore in the same period of the previous fiscal. ...

Agrochemicals manufacturer UPL on Wednesday reported 72 per cent hike in its Q4 FY21 net profit at Rs 1,065 crore from Rs 617 crore in Q4 FY20. ...

Avenue Supermarts Ltd, which owns and operates DMart stores across the country, on Saturday reported 53 increase in consolidated net profit at Rs 414 crore for the January to March 31 quarter against Rs 271 crore in the year-ago period. ...

Indian multinational Adani Enterprises said on Wednesday its January to March profit stood at Rs 413 crore, up seven times as against Rs 61 crore during the same period last year. ...

Godrej Properties said on Monday its loss totalled Rs 192 crore in Q4 FY21 due to weak home sales as compared a profit of Rs 102 crore in the same period of previous fiscal. ...

Multiplex chain Inox Leisure on Thursday reported a loss of Rs 74 crore for the fourth quarter ended March as Covid-19 led lockdowns impacted the film exhibition business. ...

Fast-moving consumer goods major Hindustan Unilever Ltd (HUL) on Thursday reported standalone net profit at Rs 2,143 crore for the March quarter (Q4 FY21), dotting an increase of 41 per cent year-on-year from Rs 1,519 crore in the same period of last ...

Biopharmaceuticals major Biocon Ltd on Thursday reported net profit of Rs 257 crore in the fourth quarter of FY21, up 95 per cent from Rs 132 crore in Q4 FY20. ...